Stock Financial Ratios, Dividends, Split History

LB / L Brands, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price31.70
Volume5,553,500.00
Market Cap ($M)9,631.76
Enterprise Value ($M)13,772.77
Book Value ($M)-971.00
Book Value / Share-3.50
Price / Book-12.79
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 280,000,000
Weighted Average Number Of Shares Outstanding Basic 284,000,000
Common Shares Outstanding 278,858,024
Weighted Average Number Of Diluted Shares Outstanding 287,000,000
Weighted Average Number Diluted Shares Outstanding Adjustment 3,000,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.20
Return on Assets (ROA)0.12
Return on Equity (ROE)-1.35
Balance Sheet (mrq) ($M)
Assets7,749.00
Liabilities8,720.00
Quick Ratio0.83
Current Ratio1.56
Income Statement (mra) ($M)
Sales Revenue Net12,632,000,000.00
Operating Income1,728.00
Net Income983.00
Earnings Per Share Diluted3.42
Earnings Per Share Basic3.46
Cash Flow Statement (mra) ($M)
Cash From Operations1,406.00
Cash from Investing-698.00
Cash from Financing-698.00
Identifiers and Descriptors
CUSIP501797104
Central Index Key (CIK)701985
Related CUSIPS
501797105 050179710 502470107 501797954 532716957 532716107

Split History

Stock splits are used by L Brands, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Market Fireworks Still Blazing

2018-07-20 seekingalpha
Heading into the July 4th holiday, US equities were in a bit of a funk with the S&P 500 down nearly 3% from its recent high in June. The July 4th holiday must have been just the rest the bulls needed, though, because since then, the S&P 500 has gone on to make a higher high with eight daily gains in the eleven trading days since July 4th. So, which sectors have been behind the market's recent strength? Leading the way higher has been Technology (what else is new?), which is up over 5%. (6-2)

Don’t Rush to Pick Up L Brands as It Continues Its Downward Spiral

2018-07-18 investorplace
L Brands (NYSE:LB), which owns franchises like Victoria’s Secret, Bath & Body Works, and Pink, has been in a horrible downward spiral this year. The shares have plunged from $60 to $32. (50-2)

5 Russell 3000 Top Dogs Fetch >24% Net Gains Per Brokers To July 2019

2018-07-18 seekingalpha
"All Russell US Indexes are subsets of the Russell 3000 Index, [namely] large-cap Russell 1000 & small-cap Russell 2000 Indexes. These Indexes are. building blocks of financial-products [and] performance-benchmarks." - FTSE Russell. (17-0)

Do Options Traders Know Something About L Brands (LB) Stock We Don't?

2018-07-17 zacks
Investors in L Brands, Inc. (LB - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $40 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.

L Brands: Are Current Dividends Safe?

2018-07-17 seekingalpha
L Brands' (NYSE:LB) current dividend yield “shines” at 7.6%, “thanks” to a price drop from $100 all-time-high to a $31.71 all-time low. Standard metrics and fair value calculations send strong buy signals.

CUSIP: 501797104